Skip main navigation

Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials

Originally publishedhttps://doi.org/10.1161/CIRCULATIONAHA.123.067512Circulation. 2024;149:981–988

BACKGROUND:

Device-detected atrial fibrillation (also known as subclinical atrial fibrillation or atrial high-rate episodes) is a common finding in patients with an implanted cardiac rhythm device and is associated with an increased risk of ischemic stroke. Whether oral anticoagulation is effective and safe in this patient population is unclear.

METHODS:

We performed a systematic review of MEDLINE and Embase for randomized trials comparing oral anticoagulation with antiplatelet or no antithrombotic therapy in adults with device-detected atrial fibrillation recorded by a pacemaker, implantable cardioverter defibrillator, cardiac resynchronization therapy device, or implanted cardiac monitor. We used random-effects models for meta-analysis and rated the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation framework (GRADE). The review was preregistered (PROSPERO CRD42023463212).

RESULTS:

From 785 citations, we identified 2 randomized trials with relevant clinical outcome data: NOAH-AFNET 6 (Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes; 2536 participants) evaluated edoxaban, and ARTESiA (Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation; 4012 participants) evaluated apixaban. Meta-analysis demonstrated that oral anticoagulation with these agents reduced ischemic stroke (relative risk [RR], 0.68 [95% CI, 0.50–0.92]; high-quality evidence). The results from the 2 trials were consistent (I2 statistic for heterogeneity=0%). Oral anticoagulation also reduced a composite of cardiovascular death, all-cause stroke, peripheral arterial embolism, myocardial infarction, or pulmonary embolism (RR, 0.85 [95% CI, 0.73–0.99]; I2=0%; moderate-quality evidence). There was no reduction in cardiovascular death (RR, 0.95 [95% CI, 0.76–1.17]; I2=0%; moderate-quality evidence) or all-cause mortality (RR, 1.08 [95% CI, 0.96–1.21]; I2=0%; moderate-quality evidence). Oral anticoagulation increased major bleeding (RR, 1.62 [95% CI, 1.05–2.50]; I²=61%; high-quality evidence).

CONCLUSIONS:

The results of the NOAH-AFNET 6 and ARTESiA trials are consistent with each other. Meta-analysis of these 2 large randomized trials provides high-quality evidence that oral anticoagulation with edoxaban or apixaban reduces the risk of stroke in patients with device-detected atrial fibrillation and increases the risk of major bleeding.

Footnotes

Supplemental Material, the podcast, and transcript are available with this article at https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.123.067512.

Continuing medical education (CME) credit is available for this article. Go to http://cme.ahajournals.org to take the quiz.

For Sources of Funding and Disclosures, see page 987.

Circulation is available at www.ahajournals.org/journal/circ .

This work was published simultaneously during the AHA Scientific Sessions, November 11–13, 2023.

Correspondence to: William F. McIntyre, MD, PhD, 237 Barton St E, DBCVSRI C3 109, Hamilton, Ontario, Canada, L8L 2X2. Email

REFERENCES

  • 1. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, et al; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke.N Engl J Med. 2012; 366:120–129. doi: 10.1056/NEJMoa1105575CrossrefMedlineGoogle Scholar
  • 2. Toennis T, Bertaglia E, Brandes A, Dichtl W, Fluschnik N, de Groot JR, Marijon E, Mont L, Blomstrom Lundqvist C, Cabanelas N, et al. The influence of atrial high rate episodes on stroke and cardiovascular death - an update.Europace. 2023; 25:euad166. doi: 10.1093/europace/euad166CrossrefMedlineGoogle Scholar
  • 3. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.Lancet. 2014; 383:955–962. doi: 10.1016/S0140-6736(13)62343-0CrossrefMedlineGoogle Scholar
  • 4. Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC, Goette A, Huening A, Lip GYH, Simantirakis E, et al. Probing oral anticoagulation in patients with atrial high rate episodes: rationale and design of the Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes (NOAH-AFNET 6) trial.Am Heart J. 2017; 190:12–18. doi: 10.1016/j.ahj.2017.04.015CrossrefMedlineGoogle Scholar
  • 5. Lopes RD, Alings M, Connolly SJ, Beresh H, Granger CB, Mazuecos JB, Boriani G, Nielsen JC, Conen D, Hohnloser SH, et al. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial.Am Heart J. 2017; 189:137–145. doi: 10.1016/j.ahj.2017.04.008CrossrefMedlineGoogle Scholar
  • 6. Kirchhof P, Toennis T, Goette A, Camm AJ, Diener HC, Becher N, Bertaglia E, Blomstrom Lundqvist C, Borlich M, Brandes A, et al; NOAH-AFNET 6 Investigators. Anticoagulation with edoxaban in patients with atrial high-rate episodes.N Engl J Med. 2023; 389:1167–1179. doi: 10.1056/NEJMoa2303062CrossrefMedlineGoogle Scholar
  • 7. Healey JS, Lopes RD, Granger CB, Alings M, Rivard L, McIntyre WF, Atar D, Birnie DH, Boriani G, Camm AJ, et al; ARTESIA Investigators. Apixaban for stroke prevention in subclinical atrial fibrillation [published online November 12, 2023].N Engl J Med. doi: 10.1056/NEJMoa2310234CrossrefGoogle Scholar
  • 8. McKibbon KA, Wilczynski NL, Haynes RB, Hedges T. Retrieving randomized controlled trials from Medline: a comparison of 38 published search filters.Health Info Libr J. 2009; 26:187–202. doi: 10.1111/j.1471-1842.2008.00827.xCrossrefMedlineGoogle Scholar
  • 9. Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients.J Thromb Haemost. 2010; 8:202–204. doi: 10.1111/j.1538-7836.2009.03678.xCrossrefMedlineGoogle Scholar
  • 10. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials.BMJ. 2019; 366:l4898. doi: 10.1136/bmj.l4898CrossrefMedlineGoogle Scholar
  • 11. Mahajan R, Perera T, Elliott AD, Twomey DJ, Kumar S, Munwar DA, Khokhar KB, Thiyagarajah A, Middeldorp ME, Nalliah CJ, et al. Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis.Eur Heart J. 2018; 39:1407–1415. doi: 10.1093/eurheartj/ehx731CrossrefMedlineGoogle Scholar
  • 12. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, deBeer H. GRADE guidelines: 1 Introduction—GRADE evidence profiles and summary of findings tables.J Clin Epidemiol. 2011; 64:383–394. doi: 10.1016/j.jclinepi.2010.04.026CrossrefMedlineGoogle Scholar
  • 13. Cardia G, Curcio A, Romano LR, Mancuso C, Fiore D, Augusto FM, Calvelli P, Indolfi C. 918 Early recognition of subclinical atrial fibrillation in patients implanted with different devices.Eur Heart J Suppl. 2022; 24:suac121.026. doi: 10.1093/eurheartjsupp/suac121.026CrossrefGoogle Scholar
  • 14. Martin DT, Bersohn MM, Waldo AL, Wathen MS, Choucair WK, Lip GYH, Ip J, Holcomb R, Akar JG, Halperin JL; IMPACT Investigators. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices.Eur Heart J. 2015; 36:1660–1668. doi: 10.1093/eurheartj/ehv115CrossrefMedlineGoogle Scholar
  • 15. Fauchier L, Villejoubert O, Clementy N, Bernard A, Pierre B, Angoulvant D, Ivanes F, Babuty D, Lip GY. Causes of death and influencing factors in patients with atrial fibrillation.Am J Med. 2016; 129:1278–1287. doi: 10.1016/j.amjmed.2016.06.045CrossrefMedlineGoogle Scholar
  • 16. Marijon E, Le Heuzey J-Y, Connolly S, Yang S, Pogue J, Brueckmann M, Eikelboom J, Themeles E, Ezekowitz M, Wallentin L, et al; RE-LY Investigators. Causes of death and influencing factors in patients with atrial fibrillation: clinical perspective.Circulation. 2013; 128:2192–2201. doi: 10.1161/CIRCULATIONAHA.112.000491LinkGoogle Scholar
  • 17. Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A, Damasceno A, Avezum A, Dans AML, Gitura B, et al; INVICTUS Investigators. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation.N Engl J Med. 2022; 387:978–988. doi: 10.1056/NEJMoa2209051CrossrefMedlineGoogle Scholar
  • 18. Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA, Patel MR, Wallentin L, Alexander JH, Cecilia Bahit M, et al; COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) Investigators. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex.Circulation. 2022; 145:242–255. doi: 10.1161/CIRCULATIONAHA.121.056355LinkGoogle Scholar
  • 19. Connolly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation.N Engl J Med. 2011; 364:806–817. doi: 10.1056/NEJMoa1007432CrossrefMedlineGoogle Scholar
  • 20. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.Ann Intern Med. 2007; 146:857–867. doi: 10.7326/0003-4819-146-12-200706190-00007CrossrefMedlineGoogle Scholar
  • 21. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, Fetsch T, van Gelder IC, Haase D, Haegeli LM, et al; EAST-AFNET 4 Trial Investigators. Early rhythm-control therapy in patients with atrial fibrillation.N Engl J Med. 2020; 383:1305–1316. doi: 10.1056/NEJMoa2019422CrossrefMedlineGoogle Scholar
  • 22. Eckardt L, Sehner S, Suling A, Borof K, Breithardt G, Crijns H, Goette A, Wegscheider K, Zapf A, Camm J, et al. Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial.Eur Heart J. 2022; 43:4127–4144. doi: 10.1093/eurheartj/ehac471CrossrefMedlineGoogle Scholar
  • 23. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, Flynn DN, et al; STOPIT-2 Study Group. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis.JAMA. 2010; 303:1180–1187. doi: 10.1001/jama.2010.310CrossrefMedlineGoogle Scholar
  • 24. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation.N Engl J Med. 2011; 365:981–992. doi: 10.1056/NEJMoa1107039CrossrefMedlineGoogle Scholar
  • 25. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation.N Engl J Med. 2013; 369:2093–2104. doi: 10.1056/NEJMoa1310907CrossrefMedlineGoogle Scholar
  • 26. Newcombe RG, Bender R. Implementing GRADE: calculating the risk difference from the baseline risk and the relative risk.Evid Based Med. 2014; 19:6–8. doi: 10.1136/eb-2013-101340CrossrefMedlineGoogle Scholar

eLetters(0)

eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.

Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.